// App-Quantinova.ai

TPS8057 : A phase III, randomized, open-label study of isatuximab (SAR650984) plus pomalidomide (Pom) and dexamethasone (Dex) versus Pom and Dex in relapsed/refractory multiple myeloma.

Researchers

Presenter

  • Paul G. Richardson

Principal Investigators

  • Michel Attal

  • Jesus San Miguel

  • Frank Campana

  • Solenn Le-Guennec

  • Ai-Min Hui

  • Marie-Laure Risse

  • Kenneth Carl Anderson

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Institut Universitaire du Cancer de Toulouse, Toulouse, France

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Sanofi Onology, Cambridge, MA

  • Sanofi R&D, Vitry-Sur-Seine, France

  • Sanofi Onology, Cambridge, MA

  • Sanofi R&D, Vitry-Alfortville, France

Locations

  • United States

  • Spain

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • carfilzomib Intravenous

  • Bortezomib

  • Isatuximab

  • Ixazomib

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

  • Prospective

Phase

  • III

Study Id's

  • NCT02990338

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved